EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A tumor-derived lactate/ENO1 lactylation feedback loop facilitates osimertinib resistance of lung adenocarcinoma

Lu Gan, Qihai Sui, Mi-Die Xu, Fei Yang, Ming Li, Yitao Yuan, Yufu Lin, Xiuping Zhang, Guoshu Bi, Wei Jiang, Qun Wang, Wei Nie und 2 weitere

Drug Resistance Updates · 2026-03 · 85 · 101346

DOI: 10.1016/j.drup.2025.101346 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2026-03. Verfasst von Lu Gan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China; Cancer Center, Zhongshan Hospital, Fudan University, Shanghai,…. Hauptthemen laut MEDLINE: Lung Neoplasms, Drug Resistance, Neoplasm, Acrylamides, Adenocarcinoma of Lung. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shanghai Municipal Natural Science Foundation, Fujian Provincial Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enhanced glycolysis and lactate accumulation are shared features of human cancers. Lactylation is a lactate-derived posttranslational modification. So far, the impact of lactylation on resistance to osimertinib (a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)) in patients with lung adenocarcinoma (LUAD) remains indistinct. Here, we performed 4D label-free proteomics analysis of LUAD tissues from advanced-stage EGFR-mutant patients treated with surgery with or without neoadjuvant osimertinib to reveal a global lactylation profile and explore the role and molecular mechanism of protein lactylation in resistance to osimertinib. Through scanning the lactylated proteome, we discovered that α-Enolase 1 (ENO1), which acts as a key glycolytic enzyme, underwent lactylation at lysine 89 (K89) in LUAD tissues. The levels of ENO1 lactylation were notably attenuated in LUAD tissues after effective osimertinib treatment and were notably elevated in osimertinib-resistant LUAD cells. We found that monocarboxylate transporters (MCTs) facilitated lactate uptake into LUAD cells for ENO1 lactylation primarily through a p300/CREB-binding protein C (CBP)-dependent mechanism. ENO1 facilitated metabolic reprogramming and lactate production and interacted with several key metabolic enzymes, such as pyruvate kinase M1 (PKM1), pyruvate kinase M2 (PKM2), lactate dehydrogenase B (LDHB), and malate dehydrogenase 2 (MDH2), thus forming a tumor-derived lactate/ENO1 lactylation feedback loop, eventually contributing to osimertinib resistance in LUAD. In the in vivo orthotopic xenograft osimertinib-resistant models, targeted suppression of the tumor-derived lactate/ENO1 lactylation feedback loop effectively ameliorated resistance to osimertinib. Collectively, our findings provide the basis for targeting lactate/lactate-associated signaling to combat resistance to osimertinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsDrug Resistance, NeoplasmAcrylamidesAdenocarcinoma of LungAniline CompoundsLactic AcidDNA-Binding ProteinsTumor Suppressor ProteinsHumansMiceAnimalsErbB ReceptorsCell Line, TumorFeedback, PhysiologicalMonocarboxylic Acid TransportersProteomicsXenograft Model Antitumor AssaysProtein Processing, Post-TranslationalProtein Kinase InhibitorsGlycolysisIndolesPhosphopyruvate HydratasePyrimidines

Stichwörter der Autor:innen

ENO1LactylationLung adenocarcinomaMCTOsimertinib resistanceP300/CBP

Substanzen

osimertinibAcrylamidesAniline CompoundsLactic AcidENO1 protein, humanDNA-Binding ProteinsTumor Suppressor ProteinsErbB ReceptorsMonocarboxylic Acid TransportersEGFR protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China; Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China; Zhangjiang Research Center, Fudan University, Shanghai, China.
  • Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Institute of Pathology, Fudan Univers…
  • Ruijin Hospital, Shanghai Jiao Tong University School, Shanghai, China.
  • Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
  • Department of Oncology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China; Clinical Research Center for Precision medicine of abdominal tumor of Fujian Province.

Förderung

  • Shanghai Municipal Natural Science Foundation
  • Fujian Provincial Natural Science Foundation

Zitieren

APA

Gan, L., Sui, Q., Xu, M. D., Yang, F., Li, M., Yuan, Y., Lin, Y., Zhang, X., Bi, G., Jiang, W., Wang, Q., Nie, W., Liu, L., & Sun, F. (2026). A tumor-derived lactate/ENO1 lactylation feedback loop facilitates osimertinib resistance of lung adenocarcinoma. Drug Resistance Updates, 85, 101346. https://doi.org/10.1016/j.drup.2025.101346

Vancouver

Gan L, Sui Q, Xu MD, Yang F, Li M, Yuan Y, et al. A tumor-derived lactate/ENO1 lactylation feedback loop facilitates osimertinib resistance of lung adenocarcinoma. Drug Resistance Updates. 2026;85:101346. doi:10.1016/j.drup.2025.101346

BibTeX
@article{Gan2026,
  author = {Gan, Lu and Sui, Qihai and Xu, Mi-Die and Yang, Fei and Li, Ming and Yuan, Yitao and Lin, Yufu and Zhang, Xiuping and Bi, Guoshu and Jiang, Wei and Wang, Qun and Nie, Wei and Liu, Liang and Sun, Fenghao},
  title = {A tumor-derived lactate/ENO1 lactylation feedback loop facilitates osimertinib resistance of lung adenocarcinoma},
  journal = {Drug Resistance Updates},
  year = {2026},
  volume = {85},
  pages = {101346},
  doi = {10.1016/j.drup.2025.101346}
}
Kostenlos starten →